Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

241.90 +1.50 (+0.62%)

Streaming Delayed Price Updated: 11:05 AM EDT, Mar 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Quiet Outperformance From an Overlooked Dividend ETF ↗

Today 8:10 EDT

Via MarketBeat

2 No-Brainer Dividend Stocks to Buy in 2026 ↗

March 08, 2026

Their futures look bright, and their dividends are safe.

Via The Motley Fool

Topics Intellectual Property

These 7 Elite Dividend Stocks Pay $114 Billion Annually, Combined, to Their Shareholders ↗

March 08, 2026

Seven of Wall Street's most influential businesses are doling out between $11.9 billion and $27.1 billion to their investors each year.

Via The Motley Fool

Topics Artificial Intelligence

Johnson & Johnson (NYSE:JNJ): A Dividend King Built for Sustainable Passive Income ↗

March 07, 2026

Via Chartmill

FDA Clears Johnson & Johnson's Multiple Myeloma Combo Drug After Strong Survival Results ↗

March 06, 2026

FDA approves Johnson & Johnson's Tecvayli with Darzalex Faspro for multiple myeloma after strong Phase 3 survival results.

Via Benzinga

Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

March 05, 2026

EQNX::TICKER_START (NNASDAQ:HELP),(CBOE:HELP),(NASDAQ:ACHC),(NYSE:JNJ),(NASDAQ:BWAY),(NASDAQ:AIFF) EQNX::TICKER_END

Via FinancialNewsMedia

2 Top Defensive ETFs That Prioritize Stability Over Excitement ↗

March 04, 2026

If you're worried about downside risk right now, here are two smart choices.

Via The Motley Fool

Topics Artificial Intelligence ETFs World Trade

ImmunityBio (IBRX) Shares Plummet Despite Piper Sandler Price Target Hike and 700% Revenue Growth

March 04, 2026

In a classic case of "selling the news," shares of ImmunityBio, Inc. (NASDAQ: IBRX) took a sharp dive on Wednesday, March 4, 2026, plummeting over 13% to close at $9.02. The sell-off came as a surprise...

Via MarketMinute

Topics Earnings Economy

The Return of the Titans: M&A Volume Set to Surge 20% in 2026 Amidst "Animal Spirits"

March 04, 2026

As of March 4, 2026, the global financial landscape is witnessing a seismic shift in corporate strategy. After years of cautious maneuvering and high interest rates, the "animal spirits" of the...

Via MarketMinute

Topics Artificial Intelligence Economy World Trade

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

March 02, 2026

From Johnson & Johnson

Via Business Wire

How to Spot Winning Innovation ↗

March 02, 2026

Author Lorraine Marchand stops by to chat.

Via The Motley Fool

Topics Artificial Intelligence

Middleby Is Spinning Off Its Food Processing Segment After a $540 Million Asset Sale. Can the Breakup Close Its Valuation Gap? ↗

February 28, 2026

Middleby is splitting up, and the sum-of-the-parts math looks promising if margins cooperate.

Via The Motley Fool

2 Reasons I'd Happily Hold Johnson & Johnson Through Any Market Crash ↗

February 27, 2026

The company has proven its resilience in the past.

Via The Motley Fool

Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability

February 26, 2026

As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster"...

Via Finterra

Topics Earnings Economy Intellectual Property

ACR Alpine Capital Research Buys 1 Million Shares of Arrow Electronics Stock ↗

February 25, 2026

Arrow Electronics is a global distributor delivering electronic components and enterprise IT solutions to industrial and commercial clients.

Via The Motley Fool

Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector ↗

February 24, 2026

Via MarketBeat

Is Johnson & Johnson Stock Outperforming the Nasdaq?

February 24, 2026

Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Via Barchart.com

Topics Stocks World Trade

Kenvue Defies Market Headwinds with Q4 Earnings Beat as Kimberly-Clark Merger Looms

February 23, 2026

In a pivotal moment for the consumer health landscape, Kenvue (NYSE: KVUE) has reported a robust set of fourth-quarter results for 2025, signaling a successful turnaround and strategic resilience just...

Via MarketMinute

Topics Earnings Economy World Trade

Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio ↗

February 22, 2026

It's about striking that perfect balance between chasing growth and protecting what you already have.

Via The Motley Fool

Topics Retirement

The Only Healthcare Stock I'd Buy and Never Sell Might Be Johnson & Johnson ↗

February 22, 2026

Johnson & Johnson stock is boring -- in a good way.

Via The Motley Fool

Economic Stagnation: Q4 2025 GDP Misses Mark as Government Shutdown Hangs Heavy Over 2026 Outlook

February 20, 2026

The U.S. economy faced a sobering reality check on Friday as the Bureau of Economic Analysis (BEA) released its preliminary reading for the fourth quarter of 2025. Gross Domestic Product (GDP) grew at...

Via MarketMinute

Topics Earnings Economy

Friday's session: gap up and gap down stock in the S&P500 index ↗

February 20, 2026

Via Chartmill

JNJ Stock Rises As Drugmaker Reportedly Eyes Orthopedics Segment Sale For Up To $20B ↗

February 19, 2026

Bloomberg reported, citing people familiar with the matter, that DePuy Synthes could be valued at more than $20 billion in a sale.

Via Stocktwits

Health Care Sector (XLV) Shows Resilience Amid Tech Volatility and Strong Jobs Data

February 18, 2026

As the broader market grappled with a violent valuation reset in the technology sector, the health care industry emerged as a critical anchor for investors in early 2026. The Health Care Select Sector...

Via MarketMinute

Topics Artificial Intelligence ETFs Earnings

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

February 18, 2026

From Johnson & Johnson

Via Business Wire

FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer ↗

February 18, 2026

FDA grants Breakthrough Therapy status to Rybrevant for advanced cancer while Trellus Health extends IBD support contract.

Via Benzinga

Behind the Scenes of Johnson & Johnson's Latest Options Trends ↗

February 17, 2026

Via Benzinga

Johnson & Johnson's New FDA Approval Lets Lung Cancer Patients Switch To Monthly Dosing Sooner ↗

February 17, 2026

FDA approves monthly dosing for J&J's Rybrevant Faspro with Lazcluze, offering faster, easier treatment for EGFR lung cancer.

Via Benzinga

The Seven-Thousand Siege: S&P 500’s Historic Breach and the Great Tech Pivot of 2026

February 16, 2026

In a watershed moment for global equity markets, the S&P 500 (INDEXSP:.INX) briefly conquered the psychological 7,000-point milestone in late January 2026, marking the fastest 1,000-point ascent in the...

Via MarketMinute

Topics Artificial Intelligence ETFs Earnings

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

February 17, 2026

From BioMedWire

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.